Takeda Pharmaceutical Company （TAK） 2020财年20-F年度报告「NYSE」.pdf

1、As filed with the Securities and Exchange Commission on June 24,2020UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,D.C.20549_FORM 20-F_REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR 12(g)OF THE SECURITIES EXCHANGE ACT OF1934ORANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECUR

2、ITIES EXCHANGE ACT OF 1934For the fiscal year ended March31,2020 ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from to ORSHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934Date of event requir

3、ing this shell company reportCommission file number:001-38757_Takeda Yakuhin Kogyo Kabushiki Kaisha(Exact name of registrant as specified in its charter)_Takeda Pharmaceutical Company Limited(Translation of registrants name into English)_Japan1-1,Nihonbashi-Honcho 2-ChomeChuo-ku,Tokyo 103-8668,Japan

4、(Jurisdiction of incorporation or organization)(Address of principal executive offices)Costa Saroukos 1-1,Nihonbashi-Honcho 2-Chome Chuo-ku,Tokyo 103-8668,Japan Tel:+81 3 3278-2306 Fax:+81 3 3278-2268(Name,Telephone,E-mail and/or Facsimile number and Address of Company Contact Person)_Securities reg

5、istered or to be registered pursuant to Section12(b)of the Act:Title of Each ClassTrading SymbolsName of Each Exchange On Which RegisteredAmerican Depositary Shares Representing Common Stock Common Stock,no par value*TAKNew York Stock Exchange*Listed not for trading,but only in connection with the r

6、egistration of the American Depositary Shares,pursuant to the requirements of the Securities and Exchange Commission.Securities registered or to be registered pursuant to Section12(g)of the Act:NoneSecurities for which there is a reporting obligation pursuant to Section15(d)of the Act:None_Indicate